Literature DB >> 31840173

Circulating angiopoietin-like protein 2 levels and mortality risk in patients receiving maintenance hemodialysis: a prospective cohort study.

Jun Morinaga1,2,3,4, Tatsuyuki Kakuma4, Hirotaka Fukami1,2, Manabu Hayata1, Kohei Uchimura5, Teruhiko Mizumoto1, Yutaka Kakizoe1, Taku Miyoshi1, Naoki Shiraishi1, Masataka Adachi1, Yuichiro Izumi1, Takashige Kuwabara1, Yusuke Okadome2, Michio Sato2, Haruki Horiguchi2, Taichi Sugizaki2, Tsuyoshi Kadomatsu2, Keishi Miyata2, Saeko Tajiri6, Tetsuya Tajiri6, Kimio Tomita1, Kenichiro Kitamura5, Yuichi Oike2, Masashi Mukoyama1.   

Abstract

BACKGROUND: Patients undergoing hemodialysis treatment have a poor prognosis, as many develop premature aging. Systemic inflammatory conditions often underlie premature aging phenotypes in uremic patients. We investigated whether angiopoietin-like protein 2 (ANGPTL 2), a factor that accelerates the progression of aging-related and noninfectious inflammatory diseases, was associated with increased mortality risk in hemodialysis patients.
METHODS: We conducted a multicenter prospective cohort study of 412 patients receiving maintenance hemodialysis and evaluated the relationship between circulating ANGPTL2 levels and the risk for all-cause mortality. Circulating ANGPTL2 levels were log-transformed to correct for skewed distribution and analyzed as a continuous variable.
RESULTS: Of 412 patients, 395 were included for statistical analysis. Time-to-event data analysis showed high circulating ANGPTL2 levels were associated with an increased risk for all-cause mortality after adjustment for age, sex, hemodialysis vintage, nutritional status, metabolic parameters and circulating high-sensitivity C-reactive protein levels {hazard ratio [HR] 2.04 [95% confidence interval (CI) 1.10-3.77]}. High circulating ANGPTL2 levels were also strongly associated with an increased mortality risk, particularly in patients with a relatively benign prognostic profile [HR 3.06 (95% CI 1.86-5.03)]. Furthermore, the relationship between circulating ANGPTL2 levels and mortality risk was particularly strong in patients showing few aging-related phenotypes, such as younger patients [HR 7.99 (95% CI 3.55-18.01)], patients with a short hemodialysis vintage [HR 3.99 (95% CI 2.85-5.58)] and nondiabetic patients [HR 5.15 (95% CI 3.19-8.32)].
CONCLUSION: We conclude that circulating ANGPTL2 levels are positively associated with mortality risk in patients receiving maintenance hemodialysis and that ANGPTL2 could be a unique marker for the progression of premature aging and subsequent mortality risk in uremic patients, except those with significant aging-related phenotypes.
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  aging; angiopoietin-like protein (ANGPTL) 2; chronic inflammation; hemodialysis; mortality risk

Year:  2020        PMID: 31840173     DOI: 10.1093/ndt/gfz236

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  4 in total

1.  The predictive role of serum calprotectin on mortality in hemodialysis patients with high phosphoremia.

Authors:  Tomoko Kanki; Takashige Kuwabara; Jun Morinaga; Hirotaka Fukami; Shuro Umemoto; Daisuke Fujimoto; Teruhiko Mizumoto; Manabu Hayata; Yutaka Kakizoe; Yuichiro Izumi; Saeko Tajiri; Tetsuya Tajiri; Kenichiro Kitamura; Masashi Mukoyama
Journal:  BMC Nephrol       Date:  2020-05-04       Impact factor: 2.388

2.  Benefits of resistant starch type 2 for patients with end-stage renal disease under maintenance hemodialysis: a systematic review and meta-analysis.

Authors:  Linpei Jia; Xingtong Dong; Xiaoxia Li; Rufu Jia; Hong-Liang Zhang
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

Review 3.  Angptl2 is a Marker of Cellular Senescence: The Physiological and Pathophysiological Impact of Angptl2-Related Senescence.

Authors:  Nathalie Thorin-Trescases; Pauline Labbé; Pauline Mury; Mélanie Lambert; Eric Thorin
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

4.  Hyperglycemia and Thrombocytopenia - Combinatorially Increase the Risk of Mortality in Patients With Acute Myocardial Infarction Undergoing Veno-Arterial Extracorporeal Membrane Oxygenation.

Authors:  Yusuke Okadome; Jun Morinaga; Hirotaka Fukami; Kota Hori; Teruhiko Ito; Michio Sato; Keishi Miyata; Takashige Kuwabara; Masashi Mukoyama; Ryusuke Suzuki; Ryusuke Tsunoda; Yuichi Oike
Journal:  Circ Rep       Date:  2021-10-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.